3 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
Follow Patient Preference: new trials by email Literature Review of Patient Preference trials Research Report on Patient Preference
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC), Pertuzumab IV, Trastuzumab IV - Early Breast Cancer, Locally Advanced Breast Cancer | Phase 3 | Completed | Hoffmann-La Roche | 346 | 2022-07-05 | 2026-02-10 |
| Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer pazopanib, sunitinib - Carcinoma, Renal Cell | Phase 3 | Completed | Novartis Pharmaceuticals | 169 | 2010-05-17 | 2017-04-17 |
| Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain Oxycodone and naloxone - Pain | Phase 3 | Completed | Mundipharma Pharmaceuticals B.V. | 174 | 2009-06-01 | 2013-02-12 |
Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Inflammatory Breast Neoplasms (1) · Neoplasms (1) · Pain (1)
Behavior (3) · Health Behavior (3) · Patient Satisfaction (3) · Treatment Adherence and Compliance (3) · Neoplasms by Site (2) · Adenocarcinoma (1) · Breast Diseases (1) · Carcinoma (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Kidney Diseases (1) · Kidney Neoplasms (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Ado-Trastuzumab Emtansine (1) · Injections, Subcutaneous (1) · Naloxone (1) · Oxycodone (1) · Radiotherapy (1) · Sunitinib (1) · Surgical Procedures, Operative (1) · Trastuzumab (1) · pazopanib (1) · pertuzumab (1)
Hoffmann-La Roche (1) · Mundipharma Pharmaceuticals B.V. (1) · Novartis Pharmaceuticals (1)
Argentina (1) · Belgium (1) · Bosnia and Herzegovina (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Chile (1) · Costa Rica (1) · Croatia (1) · Finland (1) · France (1) · Germany (1) · India (1) · Italy (1) · Kenya (1)
PMID 24687826, PMID 26457466, PMID 35011579, PMID 37146227
2008 (1), 2023 (1)